1-20 of 20
Siyang Leng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Outcomes and Adverse Events Among Patients with Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Initiating First-Line (1L) Ibrutinib: Analysis of Subgroups Receiving Subsequent Second Generation (2G) Bruton Tyrosine Kinase Inhibitors, Non-Bruton Tyrosine Kinase Inhibitor Therapy, or Ibrutinib Retreatment in the US Community Oncology Setting

John M. Burke, Ira Zackon, Brittani Wayne, Yunfei Wang, John Murphy, Jennifer Prescott, Shravanthi Gandra, Siyang Leng, Enrico De Nigris
Journal: Blood
Blood (2024) 144 (Supplement 1): 7811.
https://doi.org/10.1182/blood-2024-203667
Published: 2024
Journal Articles

Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study

Tamar Tadmor, Toby A. Eyre, Ohad Benjamini, Arvind Chaudhry, Juan Shen, Siyang Leng, Mohammed Z. H. Farooqui, David Lavie
Journal: Blood
Blood (2024) 144 (Supplement 1): 1875.2.
https://doi.org/10.1182/blood-2024-198731
Published: 2024
Journal Articles

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Marginal Zone Lymphoma: Results from the Phase 2 Bellwave-003 Study

Pier Luigi Zinzani, Juan Carlos Dupont, Alessandra Tucci, Jing Yang, Yan Xu, Siyang Leng, Muhit Ozcan
Journal: Blood
Blood (2024) 144 (Supplement 1): 3016.
https://doi.org/10.1182/blood-2024-201646
Published: 2024
Journal Articles

Real-World Clinical Outcomes in Patients Initiating Covalent Btki (cBTKi) with and without Incident Cardiovascular Adverse Events By Line of Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

David Dingli, Enrico De Nigris, Siyang Leng, Mohammed Z. H. Farooqui, Halit O. Yapici, Ian Weimer, Weiqi Jiao, Hayden W. Hyatt, Xuan Zhang, Kunal Lodaya, Mavis Obeng-Kusi
Journal: Blood
Blood (2024) 144 (Supplement 1): 3722.
https://doi.org/10.1182/blood-2024-198469
Published: 2024
Journal Articles

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study

Wojciech Jurczak, Isabelle Fleury, Antonio Pinto, Sanne Lugthart, Omur Gokmen Sevindik, Iryna Kryachok, Elizabeth Phillips, Fei Li, Chan Y. Cheah, Jing Yang, Yan Xu, Siyang Leng, Fangfang Lv
Journal: Blood
Blood (2024) 144 (Supplement 1): 1634.
https://doi.org/10.1182/blood-2024-201578
Published: 2024
Journal Articles

Healthcare Resource Utilization and Costs in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Covalent Btki (cBTKi): Real-World Impact of Cardiovascular Adverse Events

Mavis Obeng-Kusi, Enrico De Nigris, Siyang Leng, Mohammed Z. H. Farooqui, Halit O. Yapici, Ian Weimer, Weiqi Jiao, Hayden W. Hyatt, Xuan Zhang, Kunal Lodaya, David Dingli
Journal: Blood
Blood (2024) 144 (Supplement 1): 3738.
https://doi.org/10.1182/blood-2024-200345
Published: 2024
Journal Articles

Real-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study

Enrico De Nigris, Wendy Y. Cheng, Eric M. Sarpong, Siyang Leng, Mohammed Z.H. Farooqui, Uchechukwu Samuel Agu, Maryaline Catillon, Dominique Lejeune, Nathaniel Downes, Lisa Matay, Mei Sheng Duh, Scott F. Huntington
Journal: Blood
Blood (2023) 142 (Supplement 1): 6523.
https://doi.org/10.1182/blood-2023-178660
Published: 2023
Journal Articles

Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)

Matthew S. Davids, Jacob Ambrose, Enrico De Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z.H. Farooqui, Shravanthi R. Gandra, Christina M. Zettler, Laura L. Fernandes, Ching-Kun Wang, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 6536.
https://doi.org/10.1182/blood-2023-178727
Published: 2023
Journal Articles

Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up

Michael Sang Hughes, Siyang Leng, Rajshekhar Chakraborty, Divaya Bhutani, Markus Mapara, Shahzad Raza, Suzanne Lentzsch
Journal: Blood
Blood (2023) 142 (Supplement 1): 6576.
https://doi.org/10.1182/blood-2023-182842
Published: 2023
Journal Articles

Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the Real-World (rw) Practice Setting

Matthew S. Davids, Jacob Ambrose, Enrico De Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z.H. Farooqui, Shravanthi R. Gandra, Christina M. Zettler, Laura L. Fernandes, Ching-Kun Wang, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 6538.
https://doi.org/10.1182/blood-2023-180060
Published: 2023
Journal Articles

Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis

Clinical Trials & Observations
Camille Vanessa Edwards, Nisha Rao, Divaya Bhutani, Markus Mapara, Jai Radhakrishnan, Sofia Shames, Mathew S. Maurer, Siyang Leng, Alan Solomon, Suzanne Lentzsch, Andrew Eisenberger
Journal: Blood
Blood (2021) 138 (25): 2632–2641.
https://doi.org/10.1182/blood.2020009039
Published: 2021
Includes: Supplemental data
Journal Articles

Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database

Gregory S Calip, Mustafa S Ascha, Xiaoliang Wang, Amy E Pierre, Kathleen Maignan, Niquelle B Wadé, Siyang Leng, Erlene K Seymour, Brian C-H Chiu, Karen Sweiss, Pritesh R Patel, Natalia Neparidze
Journal: Blood
Blood (2021) 138 (Supplement 1): 4121.
https://doi.org/10.1182/blood-2021-152774
Published: 2021
Journal Articles

A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Arancha Alonso, MD, Miles Prince, MD, Michal Taszner, MD, Seok-Goo Cho, MD, PhD, Don A. Stevens, MD, Michelle Poon, MD, Francesca Lim, MBBS, BSc, MRCP (UK), Steven Le Gouill, MD PhD, Cecilia Carpio, MD, Mary-Margaret Keating, MD FRCPC, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Ayesha Sabir, BSc, Jingjin Li, PhD, Vladimir Jankovic, MD, Min Zhu, PhD, Jurriaan Brouwer-Visser, PhD, Siyang Leng, MD MS, L. Andres Sirulnik, MD PhD, Aafia Chaudhry, MD MBA, MS, Srikanth R. Ambati, MBBS, MD, Kim Won Seog, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-136344
Published: 2020
Journal Articles

Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Phase I/II Study

Divaya Bhutani, MD, Siyang Leng, MD, Samuel Pan, Amer Assal, MD, Alexander Wei, Julia Gould, BA, Markus Y. Mapara, MD PhD, Suzanne Lentzsch, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3196.
https://doi.org/10.1182/blood-2019-130207
Published: 2019
Journal Articles

Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101

Divaya Bhutani, MD, Siyang Leng, MD, Andrew Eisenberger, MD, Mathew S. Maurer, MD, Sofia Shames, MD, Jeff Goldsmith, PhD, Suzanne Lentzsch, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 958.
https://doi.org/10.1182/blood-2018-99-118464
Published: 2018
Journal Articles

Use of Herpes Zoster Prophylaxis in Myeloma Patients Treated with Proteasome Inhibitors

Siyang Leng, MD, Suzanne Lentzsch, MD PhD, Yanhan Shen, MS, Jason D Wright, MD MS, Dawn Hershman, MD MS, Alfred I Neugut, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2117.
https://doi.org/10.1182/blood.V130.Suppl_1.2117.2117
Published: 2017
Journal Articles

An Open-Label Phase I/II Study of Carfilzomib, Bendamustine and Dexamethasone (CBD) in Newly Diagnosed Multiple Myeloma Patients

Siyang Leng, MD, Shahzad Raza, MD, Amer Assal, MD, Gregory Baliko, BS, Julia Gould, BA, Rachel K Shields, BA, Markus Y Mapara, MD PhD, Suzanne Lentzsch, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1863.
https://doi.org/10.1182/blood.V130.Suppl_1.1863.1863
Published: 2017
Journal Articles

Final Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with Relapsed or Refractory AL Amyloidosis

Camille Vanessa Edwards, MBBS, BSc, Julia Gould, BA, Arielle L Langer, MD MPH, Markus Y Mapara, MD PhD, Jai Radhakrishnan, MD, Mathew S. Maurer, MD, Shahzad Raza, MD, John G. Mears, MD, Siyang Leng, MD, Jonathan S. Wall, PhD, Andrew Eisenberger, MD, Alan Solomon, MD, Suzanne Lentzsch, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 509.
https://doi.org/10.1182/blood.V130.Suppl_1.509.509
Published: 2017
Journal Articles

A Comparison of the Outcomes of Early Versus Delayed Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies

Siyang Leng, MD, Erin Moshier, MS, Douglas Tremblay, MD, Noa Biran, MD, Naman Barman, BS, Sundar Jagannath, MD, Ajai Chari, MD
Journal: Blood
Blood (2015) 126 (23): 1993.
https://doi.org/10.1182/blood.V126.23.1993.1993
Published: 2015
Journal Articles

A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma

Ajai Chari, MD, Hearn Jay Cho, MD PhD, Siyang Leng, MD, Amishi Dhadwal, BS, Gillian Morgan, Lisa La, MS/CCRP, Katarzyna Garcia, MS / CCRP, Crystle Carter, RN, Donna Catamero, Juliet Escalon, Erika Florendo, Nadege Stevens, RN, Daniel Verina, Moon-hee Yum, RN, Jude Gullie, BA, Elaine Chan, BS, Sundar Jagannath, MD, Violetta V Leshchenko, PhD, Alessandro Lagana, PhD, Jingjing Qi, Manishkumar Patel, Kim-Schulze Seunghee, Samir Parekh, MD
Journal: Blood
Blood (2015) 126 (23): 4226.
https://doi.org/10.1182/blood.V126.23.4226.4226
Published: 2015